Vol. 5 No. 12 (2025)
Reimbursement Recommendations

Ibrutinib

decorative image of the issue cover

Published December 4, 2025

Key Messages

  • The Formulary Management Expert Committee (FMEC) recommends that ibrutinib in combination with immunochemotherapy with or without autologous stem cell transplant (ASCT) be reimbursed for previously untreated, transplant-eligible patients with mantle cell lymphoma (MCL), provided certain conditions are met.
  • Ibrutinib in combination with immunotherapy with or without ASCT may be initiated in adults for the treatment of MCL if they meet the following conditions: they are an adult patient with untreated MCL, they are deemed transplant-eligible, and they have good performance status. A price reduction may be required.